Iron absorption in patients with chronic renal failure not requiring dialytic therapy.
Gastrointestinal iron absorption, by means of whole body counting, has been measured in 15 patients with chronic renal failure, not requiring dialysis. Whole body retention 14 days after oral administration of 10 muCi 59Fe together with a carrier dose of 10 mg Fe2+ was taken as expression of absorption. The percentage incorporation in the total erythrocyte mass of administered 59Fe (erythrocyte incorporation) and absorbed 59Fe (red cell utilization) was estimated as well. Iron absorption was 9.6+/-2.0 (S.D.)% (geometric mean) and erythrocyte incorporation 7.5+/-2.3 (S.D.)% (geometric mean) while red cell utilization averaged 80.3+/-4.8 (S.E.M.)% (arithmetic mean). None of these parameters were significantly different from those obtained in a normal control group (p greater than 0.5, p greater than 0.9 and p greater than 0.2, respectively). The correlation between iron absorption and erythrocyte incorporation was highly significant (r=1.00, p less than 0.001). Iron supplementation is often indicated in the investigated category of patients due to increased blood loss and insufficient iron intake and should be given orally in consideration of the normal gastrointestinal absorption.
D004912:Erythrocytes / Q000201:enzymology / Q000378:metabolism; D005260:Female; D005492:Folic Acid / Q000378:metabolism; D005954:Glucosephosphate Dehydrogenase / Q000097:blood; D006801:Humans; D007408:Intestinal Absorption; D007501:Iron / Q000097:blood / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000378:metabolism*; D008297:Male; D014168:Transferrin / Q000032:analysis; D014805:Vitamin B 12 / Q000097:blood
D014168:Transferrin; D005492:Folic Acid; D007501:Iron; D005954:Glucosephosphate Dehydrogenase; D014805:Vitamin B 12